Technology Bundle ID
TAB-3683

Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers

Applications
Therapeutics
Linked ID
E-274-2015-0
Lead Inventors
Thomas Flaig (University of Colorado Denver)
Co-Inventors
Andrew Thorburn (University of Colorado Denver)
Arthur Frankel (Baylor Scott & White Research Institute)
David Neville (Angimmune LLC)
Jung-hee Woo (Baylor Scott & White Research Institute)
Michael Glode (University of Colorado Denver)
This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and had limited stability. Repeated efforts to standardize the process in E. coli gave poor yields, purity, and high variation.

To overcome the problems with production using E. coli, this invention employs the Pichia pastoris strain of yeast. To produce DT390-EGF in P. pastoris, the DNA encoding the DT390-EGF protein was modified to (a) introduce an N-terminal alanine, (b) optimize codon usage for efficient translation in P. pastoris, (c) abolish N-linked glycosylation sites, and (d) add a (G4S)3 linker between the DT390 and EGF moieties. With these changes, DT390-EFG can be reproducibly produced in P. pastoris with more stability and potency compared to that produced in E. coli.
Commercial Applications
DT390-EGF has shown in vitro and in vivo efficacy in bladder cancer models.
Competitive Advantages
Production of DT390-EGF using this invention has a higher-yield and more stable product than competing methods.

Request More Info

Licensing Contact: